Loading...
Loading...
A daily tablet that acts on estrogen receptors in vaginal tissue without being estrogen, aimed at women who cannot or will not use a vaginal product. Who it suits, who it rules out, what the boxed warning means, and how it compares to the alternatives.
Most women who reach the point of asking about Osphena have already tried the obvious things. Lubricant helped a bit. A moisturiser helped a bit more. Somebody suggested vaginal estrogen, and either it was not enough, or the idea of a nightly applicator was a non starter, or a clinician was hesitant and nobody explained why.
Ospemifene is the option that tends to surface at that point, and it is genuinely different from everything else on the shelf. It is a daily tablet that acts on estrogen receptors in vaginal tissue without being estrogen. That combination is useful for a specific group of women and wrong for others, and the difference is worth understanding before an appointment rather than during one.
Start HRT online with Gala Health
Compare all providers · Take the 60-second quiz
Partner link: we may earn a commission, at no extra cost to you.
Ospemifene, sold as Osphena, is a selective estrogen receptor modulator, usually shortened to SERM. A SERM is not estrogen. It is a compound that binds to estrogen receptors and then behaves differently depending on which tissue it lands in, acting like estrogen in some places and blocking it in others.
In the case of ospemifene, the intended target is the vaginal tissue, where it behaves like estrogen: the lining thickens, becomes more elastic, and produces more natural lubrication. It is approved for moderate to severe painful sex, and also for moderate to severe vaginal dryness, where these are caused by menopausal changes to that tissue. It usually enters the conversation for painful sex specifically rather than for menopause symptoms in general.
The practical distinction that matters most to women choosing between options: this is a tablet you swallow once a day. It is not applied where the problem is. For some women that is the entire appeal.
The clearest case is a woman with moderate to severe painful sex from menopausal tissue change who cannot or would rather not use a vaginal product. That covers more people than clinicians sometimes assume. Some women find applicators physically difficult. Some find them intolerable after a history of pain. Some simply will not keep up a routine that requires the bathroom every few days, and a treatment nobody uses is not a treatment.
It is also worth considering when local treatment has genuinely been tried and has not been sufficient, rather than when it has been tried for a fortnight and abandoned. Tissue treatments of any kind take time, and switching too early usually means arriving at the second option with the same expectations that made the first one look like a failure.
This is the part to be clear about, because ospemifene carries real restrictions rather than the mild caveats attached to a moisturiser.
It carries its own boxed warning covering endometrial cancer and cardiovascular disorders. That warning is the reason suitability is a proper clinical conversation rather than a preference, and it is worth reading the current label with your prescriber rather than relying on what was written about this drug class a few years ago.
Women with undiagnosed vaginal bleeding need that investigated first, always, before any treatment of this kind. Women with a history of blood clots, stroke, or significant cardiovascular disease are generally not candidates. Breast cancer is a harder line than the phrase "discuss it with your doctor" suggests. The label states it should not be used in women with known or suspected breast cancer, or with a history of it, and it should not be combined with estrogens or with other estrogen agonist and antagonist medicines. Tamoxifen is in that second category, so a woman taking it is not a candidate for this. If you are in any of those groups and painful sex is a problem, the route forward runs through your oncology team and the non-hormonal options, not through this tablet.
If you have a uterus, ask specifically what the endometrial monitoring plan is, and what would trigger further investigation. Any bleeding that starts after you begin should be reported rather than watched.
The most commonly reported side effect is hot flashes, which surprises women who came to this hoping to avoid hormonal effects. A SERM that acts like estrogen in one tissue can behave differently elsewhere, and this one can start or worsen hot flashes in some women. It is the commonest adverse reaction rather than something most people should expect. For a woman whose hot flashes have already settled, that trade deserves thought. For a woman still having them, it may make the decision harder rather than simpler.
Other reported effects include vaginal discharge, muscle spasms and sweating. None of that is universal, and for many women the tablet is uneventful.
On timing, treat this as a tissue treatment rather than a painkiller. Improvement builds over weeks to a few months rather than days, and judging it after two weeks will tell you nothing useful. Give it a fair run, keep a short record of whether penetration is becoming easier rather than whether any single occasion was painful, and review with the person who prescribed it.
Start HRT online with Gala Health
Compare all providers · Take the 60-second quiz
Partner link: we may earn a commission, at no extra cost to you.
Two misunderstandings come up often enough to be worth heading off.
It is not a systemic hormone therapy and it is not a substitute for one. If your main problems are hot flashes, night sweats, disrupted sleep or mood, ospemifene is aimed somewhere else entirely, and as noted above it may make vasomotor symptoms worse rather than better. Women sometimes arrive hoping one tablet will address everything, and this is not that tablet.
It is also not primarily a urinary treatment. The genitourinary changes of menopause affect the bladder and urethra as well as the vagina, and local estrogen is the option with the track record for the urinary side. If recurrent urinary tract infections or urgency are as much of a problem as painful sex, say so explicitly, because it may change which option makes sense first.
Not working can mean two different things and they lead in different directions.
If symptoms have improved but not enough, that is a conversation about time and about combining approaches. Non-hormonal moisturisers and lubricants remain useful alongside a prescription treatment rather than being replaced by it, and adding them back is not a step backwards.
If nothing has changed at all after a fair trial, the question is whether the diagnosis is complete. Painful sex after menopause is usually tissue related, but not always. Pelvic floor tension, vulval skin conditions such as lichen sclerosus, and other causes produce pain that no amount of tissue treatment resolves, and they need identifying rather than out-treating. A clinician who examines rather than only prescribes is what moves that forward.
Against vaginal estrogen, the trade is route and reach. Local estrogen puts a small dose exactly where the problem is, which is why it is usually the first line offered, and it also helps urinary symptoms in a way ospemifene is not primarily aimed at. Ospemifene wins on convenience for women who will not use a local product. Our vaginal estrogen page sets out how the local options differ from one another.
Against vaginal DHEA, the comparison is closer than most women expect, and we have written it up separately in DHEA versus vaginal estrogen. DHEA is also a local insert rather than a tablet, so the same route question applies.
Against moisturisers and lubricants, this is not really a competition. Non-hormonal products are the right first step for mild symptoms and remain useful alongside any prescription treatment, but they are generally not enough on their own once symptoms are moderate to severe. We go through the practical differences in vaginal dryness and painful sex.
The appointment prep tool will put that list on one page, which matters when the appointment is short and the topic is one many women find hard to raise at all.
Ospemifene is a daily tablet for moderate to severe painful sex after menopause, aimed squarely at women who cannot or will not use a vaginal product. It is not estrogen, but it is not a gentle over the counter option either: it carries a boxed warning, it has real contraindications, and a history of breast cancer or current tamoxifen rules it out rather than merely complicating it.
Used in the right person it solves a problem that lubricant alone does not touch, and painful sex is worth solving rather than tolerating. If nobody has walked you through the options, our page on painful intercourse covers the wider picture, our directory lists menopause specialists by state, and telehealth services reach most of the country. For background guidance see The Menopause Society.
Start HRT online with Gala Health
Get a licensed clinician, a prescription if HRT is right for you, and treatment shipped to your door - without an in-person visit.
Not sure which platform fits you? Take the 60-second match quiz or compare the best online HRT of 2026.
How getting started works
Share your health history
A short online questionnaire, about 5 minutes. No appointment and no waiting room.
A licensed clinician reviews
A licensed provider checks your history and, if HRT is right for you, writes the prescription.
Delivered to your door
Your treatment ships to you, usually within days, with ongoing check-ins and dose adjustments.
Some links above are partnerships. If you start care through them, we may earn a commission at no extra cost to you. Partners we can earn from may be shown first in some lists, but commission never changes the facts we report about any provider.
The information on FindMyHRT is for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment. Never disregard professional medical advice or delay seeking it because of something you have read on this website.
Everything you need before your first appointment, in one guide you can print:
Free. We'll email you the kit, then three short notes over the next ten days or so. Unsubscribe anytime. We never share your email.